Cardiac Sarcoidosis: A Clinical Overview |
| |
| Institution: | 1. Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada;2. Echocardiography, Cardioestudio, Clinica Las Vegas, Medellin, Colombia;3. Division of Respiratory Medicine, Mount Sinai Hospital and University Health Network, Toronto, Ontario, Canada;4. Department of Cardiology and Heart Failure, Sanatorio Güemes, Buenos Aires, Argentina;1. Department of Internal Medicine, Ochsner Health Foundation, New Orleans, LA;2. Department of Cardiovascular Health, Ochsner Health Foundation, New Orleans, LA;3. The University of Queensland Faculty of Medicine, Herston, Australia;4. Department of Internal Medicine, University of Maryland Capital Regional Medical Center, Largo, MD;1. John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA;2. King Salman Heart Center, King Fahd Medical City, Riyadh, Saudi Arabia;3. Section of Cardiomyopathy & Heart Transplantation, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA;4. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA;1. Leonard J. Chabert Medical Center, Houma, LA;2. John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA;3. The University of Queensland Ochsner Clinical School, Faculty of Medicine, The University of Queensland, New Orleans, LA;4. Department of Internal Medicine, Montefiore Medical Center Wakefield Campus, The Bronx, NY;1. Cleveland Clinic, Respiratory Institute, Cleveland, OH;2. Cleveland Clinic, Heart and Vascular Institute, Cleveland, OH;3. Mater Misericordiae University Hospital, Department of Cardiology, Dublin, Ireland;1. Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX;2. UCF College of Medicine/HCA Ocala Internal Medicine, Ocala, FL |
| |
| Abstract: | Cardiac sarcoidosis (CS) with clinical manifestation occurs in about 5-8% of patients with sarcoidosis. CS may be clinically suspected by the presence of ventricular arrhythmia, conduction abnormalities, and heart failure (HF). However, 20%-25% of patients may present with silent CS, having asymptomatic cardiac involvement. The diagnosis of CS is based on findings from nuclear studies, cardiac magnetic resonance, and extra-cardiac tissue biopsy. Due to the inflammatory nature of the disease, immunosuppressive medications are a cornerstone of therapy. The treatment also includes recommended HF medical therapies. Since CS patients are at risk of sudden cardiac death resulting from progression of cardiac dysfunction or the presence of scar originating from fatal arrhythmias, implantable cardioverter-defibrillators should be considered, with special indication beyond accepted recommendations in HF. In CS, the extent of left ventricular dysfunction is the most important mortality predictor. Heart transplant or mechanical circulatory support may represent life saving strategies in selective CS patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
